Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Key Points

Key points are not available for this paper at this time.

Abstract

This analysis confirms the IDFS benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early BC. Longer follow-up is needed to fully assess OS benefit.

Read Full Paperexternally

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Journal of Clinical Oncology

Institutions

Harvard University

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.